BI

Bionyra

6 known investors

bionyra.com ↗

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.

Investors · 6

JE

Jeito Capital✓ verifiedParis

SA

Sanofi Ventures✓ verifiedCambridge · $5M

SO

Sofinnova Partners✓ verifiedParis · $540K – $27M

AP

Apollo Health Ventures✓ verifiedBerlin

SI

Sixty Degree Capital✓ verifiedNorth York

VI

VIVES Partners✓ verifiedWavre · $108K – $7.6M